Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Vaccines01:30

Cancer Vaccines

884
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
884
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tetraploidy in cancer: Diagnostic and therapeutic perspectives.

Biochemical pharmacology·2026
Same author

ASO Visual Abstract: Immediate Second Look After Cytoreduction for Colorectal or Ovarian Carcinomatosis: An Invisible Gorilla Effect?

Annals of surgical oncology·2026
Same author

Immediate Second Look After Cytoreduction for Colorectal or Ovarian Carcinomatosis: An Invisible Gorilla Effect?

Annals of surgical oncology·2026
Same author

Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice.

Bone research·2026
Same author

<i>Atg5</i>/Autophagy inactivation in mouse bone microenvironment promotes tumor development.

Autophagy·2026
Same author

Deciphering the interaction between osteosarcoma and mesenchymal stem cells in a 3D bone-mimetic co-culture model.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Related Experiment Video

Updated: Dec 30, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K

Bone sarcomas in the immunotherapy era.

Marie-Françoise Heymann1,2,3, Kristina Schiavone1,2, Dominique Heymann1,2,3

  • 1Université de Nantes, INSERM, CRCINA, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

British Journal of Pharmacology
|January 25, 2020
PubMed
Summary
This summary is machine-generated.

Bone sarcomas, including osteosarcoma and Ewing's sarcoma, are entering the immunotherapy era. Further characterization of the tumor microenvironment is crucial for improving patient responses to these novel treatments.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.1K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Related Experiment Videos

Last Updated: Dec 30, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.1K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Area of Science:

  • Oncoimmunology
  • Translational Oncology
  • Pediatric Oncology

Background:

  • Bone sarcomas are rare primary bone tumors predominantly affecting children, adolescents, and adults in their 40s.
  • Traditional therapeutic approaches, including drug combinations, have yielded limited improvements in overall survival for bone sarcomas.
  • Recent advances in oncoimmunology highlight the immune system's critical role in cancer, prompting new therapeutic strategies.

Purpose of the Study:

  • To review recent developments in immunotherapies for bone sarcomas.
  • To emphasize the need for improved characterization of the tumor microenvironment for enhanced immunotherapeutic responses.
  • To discuss the potential of immunotherapy, particularly in pediatric bone sarcoma forms.

Main Methods:

  • Characterization of immune infiltrates in bone sarcomas.
  • Molecular profiling to identify immune therapeutic targets.
  • Overview of recent clinical trials and developments in bone sarcoma immunotherapy.

Main Results:

  • Immune infiltrates and molecular targets in bone sarcomas have been identified.
  • Clinical responses to current immunotherapies in bone sarcomas remain largely anecdotal.
  • The study highlights the necessity for improved tumor microenvironment characterization.

Conclusions:

  • Bone sarcomas are now part of the immunotherapy landscape.
  • Enhanced understanding of the tumor microenvironment is essential to unlock effective immunotherapeutic strategies.
  • Future research should focus on optimizing immunotherapies, especially for pediatric bone sarcomas.